Ellagic Acid, Kaempferol, and Quercetin from Acacia nilotica: Promising Combined Drug With Multiple Mechanisms of Action

被引：46
作者：
Al-Nour M.Y. [1 ]
Ibrahim M.M. [1 ]
Elsaman T. [1 ]
机构：
[1] Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Omdurman Islamic University, Omdurman
来源：
Current Pharmacology Reports | 2019年 / 5卷 / 4期
关键词：
A; nilotica; ADMET and computer-aided drug discovery; Ellagic acid; Kaempferol; Multiple mechanisms of action; Quercetin;
D O I：
10.1007/s40495-019-00181-w
中图分类号：
学科分类号：
摘要：
The pharmacological activity of Acacia nilotica’s phytochemical constituents was confirmed with evidence-based studies, but the determination of exact targets that they bind and the mechanism of action were not done; consequently, we aim to identify the exact targets that are responsible for the pharmacological activity via the computational methods. Furthermore, we aim to predict the pharmacokinetics (ADME) properties and the safety profile in order to identify the best drug candidates. To achieve those goals, various computational methods were used including the ligand-based virtual screening and molecular docking. Moreover, pkCSM and SwissADME web servers were used for the prediction of pharmacokinetics and safety. The total number of the investigated compounds and targets was 25 and 61, respectively. According to the results, the pharmacological activity was attributed to the interaction with essential targets. Ellagic acid, Kaempferol, and Quercetin were the best A. nilotica’s phytochemical constituents that contribute to the therapeutic activities, were non-toxic as well as non-carcinogen. The administration of Ellagic acid, Kaempferol, and Quercetin as combined drug via the novel drug delivery systems will be a valuable therapeutic choice for the treatment of recent diseases attacking the public health including cancer, multidrug-resistant bacterial infections, diabetes mellitus, and chronic inflammatory systemic disease. © 2019, Springer Nature Switzerland AG.
引用
收藏
页码：255 / 280
页数：25
相关论文
共 91 条
[41]  
Roskoski R., The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders, Pharmacol Res, 129, pp. 65-83, (2018)
[42]  
Roskoski Jr R., Src protein-tyrosine kinase structure and regulation, Biochem Biophys Res Commun, 324, pp. 1155-1164, (2004)
[43]  
Sivonova M.K., Jurecekova J., Tatarkova Z., Kaplan P., Lichardusova L., Hatok J., The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition, Gen Physiol Biophys, 36, pp. 487-499, (2017)
[44]  
Lehtio L., Chi N.W., Krauss S., Tankyrases as drug targets, FEBS J, 280, pp. 3576-3593, (2013)
[45]  
Leao R., Apolonio J.D., Lee D., Figueiredo A., Tabori U., Castelo-Branco P., Mechanism oh human telomerase reverse transcriptase (hTERT) regulation: clinical impact in cancer, J Biomed Sci, 25, (2018)
[46]  
Xia Y., Shen S., Verma I.M., NF-<sup>k</sup>B, an active player in human cancers, Cancer Immunol Res, 2, pp. 823-830, (2014)
[47]  
Goldenberg-Furmanov M., Stein I., Pikarsky E., Rubin H., Kasem S., Wygoda M., Weinstein I., Reuveniand H., Ben-Sasson S.A., Lyn is a target gene for prostate cancer sequence-based inhibition induces regression of human tumor xenografts, Cancer Res, (2004)
[48]  
Neufeld G., Cohen T., Gengrinovitich S., Poltorak Z., Vascular endothelial growth factor (VEGF) and its receptors, FASEB J, 13, pp. 9-22, (1999)
[49]  
Torsten Schwede J.K., Guex N., Peitsch M.C., SWISS-MODEL: an automated protein homology-modeling server, Nucleic Acids Res, 31, pp. 3381-3385, (2003)
[50]  
Zitko J., Dolezal M., Enoyl-acyl carrier protein reductase inhibitors:n an updated patent review, Expert Opin Ther Pat, 26, pp. 1079-1094, (2016)
12345678910